Significant improvement found in patients with RLS.
The first double-blind, placebo-controlled study of Requip in patients with restless legs syndrome (RLS) showed the drug led to significant improvement in the periodic leg movements (PLMS) of sleep. The primary outcome measure was to determine whether the number of leg movements per hour in NREM sleep was reduced in patients treated with Requip vs. placebo-treated patients. Patients with primary RLS (n=31) were started on 0.25 mg/dose of Requip administered in the evening, and then maintained at that dosage for 2 weeks. The dose of Requip ranged from 0.25 to 6 mg/day with an average of 1.7 mg/day.